ReviewFrontiers in immunology2026
The complement system in Alzheimer's disease: mechanisms, biomarkers, and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder in which synaptic loss is closely associated with cognitive decline. Although the amyloid hypothesis has long dominated AD research, the limited efficacy of amyloid-targeted therapies highlights the need to explore additional pathogenic mechanisms. Increasing evidence indicates that dysregulation of the complement system plays a critical role in AD, linking genetic risk, protein aggregation, neuroinflammation, and neurodegeneration. Under physiological conditions, complement signaling is essential for neural development and synaptic refinement; however, in AD, aberrant activation contributes to excessive synaptic pruning and sustained inflammatory responses. As a result, complement components have attracted attention as potential biomarkers and therapeutic targets, despite limitations in disease specificity. This review summarizes current advances in understanding complement system alterations in AD, discusses their roles in disease pathogenesis, and highlights emerging complement-targeted therapeutic strategies, as well as remaining challenges related to intervention timing, patient stratification, and blood-brain barrier delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.